The pharma company will analyze genomic and clinical data from 2 million individuals over the next 10 years to drive drug development across its entire portfolio.
Cepheid, MedImmune, COMBACTE Ink Bacterial Dx Collaboration
Cepheid will create Xpert cartridge tests to detect S. aureus and P. aeuginosa, to be used in clinical trials for biologics intended to prevent pneumonia.
While the deal has provided AstraZeneca and MedImmune access to the tissue phenomics technology, Definiens now has broader and clearer access to patients.
AstraZeneca's MedImmune Acquiring Definiens for at Least $150M
NEW YORK (GenomeWeb) – AstraZeneca today announced its biologics research and development arm MedImmune has reached a deal to purchase digital pathology products firm Definiens.
AstraZeneca, U of Cambridge Collaboration to Include R&D into Neurodegenerative Diseases
NEW YORK (GenomeWeb) – AstraZeneca and its wholly owned subsidiary MedImmune announced on Thursday collaborations with the University of Cambridge, including one aimed at research into neurodegenerative diseases.
Jun 4, 2014
Ventana to Develop CDx for MedImmune NSCLC Drug
Jul 1, 2011
Mar 30, 2009
Around the Regions: Mar 30, 2009
Feb 23, 2009